Clinical Trial Update: An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ixmyelocel-T via transendocardial injections for heart failure due to ischemic dilated cardiomyopathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemic Dilated Cardiomyopathy

Drugs mentioned

• Ixmyelocel-T (Ixmyelocel-T)

Snippet

Sponsor: Vericel Corporation | Conditions: Ischemic Dilated Cardiomyopathy (IDCM) | Phase 2 | Status: COMPLETED